John DiPersio, MD, PhD

Drs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.

Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.

Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.

Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.

Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.

John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.

John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.

Michael Bishop, MD, leads the discussion on approaching the first-line management of acute GVHD and the importance of early intervention for patients at risk for the disease.

Expert hematologist-oncologists provide insight on major risk factors for GVHD and associated challenges for treatment.

Dr John DiPersio discusses an early intervention approach to the management of chronic and acute GVHD.

John DiPersio, MD, PhD, and Michael Bishop, MD, define acute and chronic graft-vs-host disease (GVHD).

A key opinion leader provides insight into recent data updates from ongoing trials studying the management of GvHD with promising regimens. 

John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.